In 478 patients with high-risk low-grade (WHO grade 2) glioma, first-line temozolomide versus radiotherapy made no significant difference to progression-free or overall survival in mature phase III results; post hoc molecular subgroups (351 analysable) showed similar results.
Secondary analysisn = 478
Baumert et al. Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)